A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Conditions:   Breast Cancer;   HER2+ Breast Cancer Interventions:   Biological: VRP-HER2;   Biological: Pembrolizumab Sponsors:   Herbert Lyerly;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials